Skip to main content

Table 4 Autoantibodies in different disease subsets in 863 individual systemic sclerosis patients

From: Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features

  Limited (N= 513) Diffuse (N= 173) Overlap (N= 108) Undifferentiated (N= 64)
Antibodies n(%) ORa (P-value) n(%) OR (P-value) n(%) OR (P-value) n(%)
ACA 253 (49.3) 5.00 ( P < 0.0001) 12 (6.9)   16 (14.8)   28 (43.8)
ATA 141 (27.5)   98 (56.6) 4.26 ( P < 0.0001) 11 (10.2)   9 (14.1)
Anti-RNAP 14 (2.7)   14 (8.1) 3.11 ( P = 0.0029) 2 (1.9)   2 (3.1)
Anti-U1-RNP 7 (1.4)   0 (0.0)   31 (28.7) 30.00 ( P < 0.0001) 2 (3.1)
Anti-PM-Scl 16 (3.1)   2 (1.2)   22 (20.4) 9.40 ( P < 0.0001) 2 (3.1)
Anti-fibrillarin 3 (0.6)   8 (4.6) 8.32 ( P = 0.0005) 1 (0.9)   0 (0.0)
Anti-To 1 (0.2)   0 (0)   1 (0.9)   0 (0.0)
Anti-Jo-1/Pl-7/OJ 0 (0.0)   0 (0)   4 (3.7) 65.07 ( P = 0.0002) 0 (0.0)
Anti-U11-RNP 0 (0.0)   1 (0.6)   0 (0.0)   0 (0.0)
Anti-Ku 5 (1.0)   1 (0.6)   3 (2.8)   1 (1.6)
Anti-SL 5 (1.0)   3 (1.7)   1 (0.9)   0 (0.0)
Anti-Sm 0 (0.0)   0 (0.0)   3 (2.8) 21.54 (P = 0.0069) 0 (0.0)
Anti-NOR-90 5 (1.0)   0 (0.0)   1 (0.9)   0 (0.0)
AMA 28 (5.5)   4 (2.3)   4 (3.7)   5 (7.8)
Anti-Sp100 3 (0.6)   0 (0.0)   0 (0.0)   1 (1.6)
Anti-Ro52 125 (24.4) 1.50 (P = 0.023) 20 (11.6)   27 (25.0)   15 (23.4)
Anti-Ro60 28 (5.4)   14 (8.1)   13 (12.0) 2.11 (P = 0.0382) 4 (6.3)
Anti-La 9 (1.8)   3 (1.7)   1 (0.9)   3 (4.7)
Anti-p25/p23 24 (4.5) 4.25 ( P = 0.0031) 0 (0.0)   2 (1.9)   2 (3.1)
Other 209 (40.7)   74 (42.8)   44 (40.7)   34 (53.1)
ANA-negative 32 (6.2)   6 (3.5)   5 (4.6)   7 (10.9)
  1. ACA, anti-centromere antibodies; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; ATA, anti-topoisomerase I antibodies; RNAP, RNA polymerase;. aOR for antibody in that subset compared with all other subsets. Only significant positive associations are documented by OR, and those with P-values < 0.005 are printed in bold.